Amgen's PCSK9 inhibitor prevails in third Phase III study
This article was originally published in Scrip
Amgen reported positive top-line results from the third of 13 Phase III clinical trials for the company's cholesterol-lowering biologic evolocumab (AMG 145), which met the GAUSS-2 study's co-primary endpoints in the treatment of 307 statin-intolerant patients.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.